CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial

Recruiting now · Not applicable

Conditions studied: Breast Cancer, Circulating Tumor Cell

In brief

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.

Key facts

Study ID

NCT05360290

Run by

RenJi Hospital

People needed

484

Starts

2022-09-14

Expected to finish

2029-06-01

Last updated by the study team

2026-02-03

Who can join

Age: 18 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female, aged ≥18 and ≤70 years;
• Histologically confirmed invasive breast cancer (cT2-4N0-2M0 or cT1N1-3M0 before neoadjuvant treatment);
• Completed neoadjuvant treamtment and surgery (within 4 years after surgery);
• Administered neoadjuvant chemotherapy (regardless of chemotherapy regimen);
• ECOG 0-1

You may not qualify if…

• Metastatic disease (Stage IV);
• Female patients who are pregnancy or lactation;
• Uncontrollable puncture site infection or systemic infection;

Where it is running

• Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.